Chemistry:Firategrast
From HandWiki
Firategrast (SB-683699) is an experimental drug which is an orally active and selective antagonist of the α4β1 and α4β7 integrin receptors. It reduces trafficking of lymphocytes into the central nervous system, and is in clinical trials for the treatment of multiple sclerosis. It may also have application in the treatment of breast cancer.[1][2][3]
References
- ↑ "Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial". The Lancet. Neurology 11 (2): 131–139. February 2012. doi:10.1016/S1474-4422(11)70299-X. PMID 22226929.
- ↑ "Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis". Journal of Internal Medicine 289 (6): 771–791. June 2021. doi:10.1111/joim.13215. PMID 33258193.
- ↑ "Introduced the ITGB1-DT as a novel biomarker associated with five potential drugs using bioinformatics analysis of breast cancer proteomics data and RT-PCR". Molecular and Cellular Probes 71. October 2023. doi:10.1016/j.mcp.2023.101930. PMID 37690573.
 |  |
